Virpax Pharmaceuticals appoints Ruskin to board of directors

Virpax Pharmaceuticals (VRPX) announced that the Company has appointed Barbara Ruskin, Ph.D, J.D. to its Board of Directors, increasing the size of the Board to nine members. Most recently Dr. Ruskin serves as the Chief Intellectual Property and Innovation Officer for Silence Therapeutics (SLN)